Magdy Helmy Megallaa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Magdy Helmy Megallaa has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Abdelaziz Elnekeidy
Department of Radio-diagnosis, Faculty of Medicine, Alexandria University, Alexandria, Egypt
1 shared publication - Alaa M. Wafa
Diabetes and Endocrinology Unit, Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
1 shared publication - Azza A. Ismail
Unit of Diabetes, Lipidology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria 21526, Egypt
1 shared publication - Bahaa Sharafeldeen
Egyptian Ministry of Health, Cairo 11516, Egypt
1 shared publication - Eman Youssef Moursy
Diabetes & Metabolism Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
1 shared publication Gihane I. Khalil
Department of Chemical Pathology, Medical Research, University of Alexandria, Alexandria, Egypt
1 shared publication
Latest Publications
- Open Access
- 6 May 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (5) , 90
Simplifying Treatment for Type 2 Diabetes: Egyptian Consensus Recommendations on Fixed-Ratio Combinations
Background/Objectives: Egypt ranks among the top ten countries globally with the highest burden of type 2 diabetes mellitus (T2DM), with prevalence projected to rise significantly by 2050. Despite multiple therapeutic options, glycemic control remains suboptimal due to therapeutic inertia, treatment complexity, and healthcare system limitations. Fixed-ratio combinations (FRCs) of basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer a simplified injectable strategy addressing complementary pathophysiological defects in T2DM. This study aims to develop expert consensus recommendations for the use of FRCs in Egyptian adults with T2DM, integrating international evidence with local practice. Methods: A modified Delphi technique was employed to achieve consensus among 9 diabetes experts across Egypt. Statements were formulated based on a targeted literature review and voted on using a structured Likert scale. Consensus was defined as ≥70% agreement. Results: Twenty-nine statements were endorsed with strong to very strong consensus. Recommendations covered patient selection, initiation after oral therapy or GLP-1 RA, switching from premixed or complex insulin regimens, dosing strategies, safety considerations, and intensification options. FRCs were favored for early injectable use, regimen simplification, and improved adherence, with liraglutide-based FRCs preferred for cardiovascular and renal benefits. Digital health integration was strongly recommended to enhance glycemic control and patient engagement. Conclusions: FRCs offer a simple and effective treatment simplification option for patients with uncontrolled T2DM on premix insulin, complex insulin regimens, or oral therapy. FRCs may improve glycemic control with generally favorable effects on hypoglycemia risk and body weight across many randomized and real-world studies, while reducing injection burden, simplifying the treatment regimen, and supporting patient adherence and satisfaction.
- 6 May 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (5) , 90
Open AccessSimplifying Treatment for Type 2 Diabetes: Egyptian Consensus Recommendations on Fixed-Ratio Combinations
Background/Objectives: Egypt ranks among the top ten countries globally with the highest burden of type 2 diabetes mellitus (T2DM), with prevalence projected to rise significantly by 2050. Despite multiple therapeutic options, glycemic control remains suboptimal due to therapeutic inertia, treatment complexity, and healthcare system limitations. Fixed-ratio combinations (FRCs) of basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer a simplified injectable strategy addressing complementary pathophysiological defects in T2DM. This study aims to develop expert consensus recommendations for the use of FRCs in Egyptian adults with T2DM, integrating international evidence with local practice. Methods: A modified Delphi technique was employed to achieve consensus among 9 diabetes experts across Egypt. Statements were formulated based on a targeted literature review and voted on using a structured Likert scale. Consensus was defined as ≥70% agreement. Results: Twenty-nine statements were endorsed with strong to very strong consensus. Recommendations covered patient selection, initiation after oral therapy or GLP-1 RA, switching from premixed or complex insulin regimens, dosing strategies, safety considerations, and intensification options. FRCs were favored for early injectable use, regimen simplification, and improved adherence, with liraglutide-based FRCs preferred for cardiovascular and renal benefits. Digital health integration was strongly recommended to enhance glycemic control and patient engagement. Conclusions: FRCs offer a simple and effective treatment simplification option for patients with uncontrolled T2DM on premix insulin, complex insulin regimens, or oral therapy. FRCs may improve glycemic control with generally favorable effects on hypoglycemia risk and body weight across many randomized and real-world studies, while reducing injection burden, simplifying the treatment regimen, and supporting patient adherence and satisfaction.
- Open Access
- 10 March 2016
- Published by SAGE Publications in Therapeutic Advances in Endocrinology and Metabolism
- Vol. 7 (2) , 47-56
Serum chemerin and high-sensitivity C reactive protein as markers of subclinical atherosclerosis in Egyptian patients with type 2 diabetes
Chemerin is one of the adipokines that regulate fat metabolism. High-sensitivity C-reactive protein (hs-CRP) may be considered as a cardiovascular risk predictor. Measuring intima-media thickness of the CCA (C-IMT) is a well-evidenced tool for the detection of early stages of atherosclerosis. We aimed here to study both serum chemerin and hs-CRP as markers of subclinical atherosclerosis in Egyptian patients with type 2 diabetes, who are angiographically free of coronary artery disease (CAD). This cross-sectional study was conducted on 180 subjects divided into two groups: Group A included 90 type 2 diabetic patients without CAD and group B including 90 nondiabetic control subjects. All study subjects were having normal coronary angiography. Serum chemerin, homeostasis model assessment for insulin resistance (HOMA-IR), glycated haemoglobin (HbA1c), lipid profile, hs-CRP as well as C-IMT were assessed in all study subjects. There was a statistically significant difference between the 2 groups regarding serum chemerin level, HOMA-IR, hs-CRP and C-IMT; being higher in the diabetic patients than in the control group (p = 0.006, 0.024, 0.040 and p = 0.006 and 0.032, respectively), and negatively correlated with HDL-cholesterol level (p = 0.018). Both serum chemerin and hs-CRP could be considered as markers of subclinical atherosclerosis, and hence, may be utilized for the early detection of macrovascular disease, in Egyptian patients with type 2 diabetes.
- 10 March 2016
- Published by SAGE Publications in Therapeutic Advances in Endocrinology and Metabolism
- Vol. 7 (2) , 47-56
Open AccessSerum chemerin and high-sensitivity C reactive protein as markers of subclinical atherosclerosis in Egyptian patients with type 2 diabetes
Chemerin is one of the adipokines that regulate fat metabolism. High-sensitivity C-reactive protein (hs-CRP) may be considered as a cardiovascular risk predictor. Measuring intima-media thickness of the CCA (C-IMT) is a well-evidenced tool for the detection of early stages of atherosclerosis. We aimed here to study both serum chemerin and hs-CRP as markers of subclinical atherosclerosis in Egyptian patients with type 2 diabetes, who are angiographically free of coronary artery disease (CAD). This cross-sectional study was conducted on 180 subjects divided into two groups: Group A included 90 type 2 diabetic patients without CAD and group B including 90 nondiabetic control subjects. All study subjects were having normal coronary angiography. Serum chemerin, homeostasis model assessment for insulin resistance (HOMA-IR), glycated haemoglobin (HbA1c), lipid profile, hs-CRP as well as C-IMT were assessed in all study subjects. There was a statistically significant difference between the 2 groups regarding serum chemerin level, HOMA-IR, hs-CRP and C-IMT; being higher in the diabetic patients than in the control group (p = 0.006, 0.024, 0.040 and p = 0.006 and 0.032, respectively), and negatively correlated with HDL-cholesterol level (p = 0.018). Both serum chemerin and hs-CRP could be considered as markers of subclinical atherosclerosis, and hence, may be utilized for the early detection of macrovascular disease, in Egyptian patients with type 2 diabetes.
- Open Access
- 23 October 2015
- Published by Science Publishing Group in American Journal of Internal Medicine
- Vol. 3 (6) , 250-255
Relationship Between Neutrophil-Lymphocyte Ratio and Microvascular Complications in Egyptian Patients with Type 2 Diabetes
Several epidemiological studies have shown that chronic inflammation plays a central role in the pathogenesis of diabetes and its various complications. Neutrophil-lymphocyte ratio (NLR) is a novel potential marker in determining inflammation. The aim of this study was to evaluate the relationship between diabetic microvascular complications, namely diabetic retinopathy, nephropathy, neuropathy, and neutrophil-lymphocyte ratio in type 2 diabetic patients. The study took place in the Unit of Diabetes & Metabolism at the Faculty of Medicine, Alexandria University, Alexandria, Egypt, and included a total of 280 subjects, 200 male patients with type 2 diabetes, 108 of them having one or more microvascular complication, and a control group including 80 healthy age and sex-matched subjects. Results of our study showed that neutrophil-lymphocyte ratio (NLR) values were significantly higher in diabetic patients with retinopathy (p<0.001), neuropathy (p=0.025) and nephropathy (p<0.001) than those of diabetic patients without any microvascular complications and healthy control subjects. NLR levels correlated positively with body mass index (BMI) (r=0.436, p<0.001), glycosylated hemoglobin (HbA1c) (r=0.526, p=0.001) and erythrocyte sedimentation rate (ESR) (r=0.396, p=0.017). Based on the results of this study, we can conclude that neutrophil-lymphocyte ratio (NLR), which is an efficient, simple and stable marker of inflammation, can serve as an important predictor for the presence of microvascular complications in Egyptian patients with type 2 diabetes.
- 23 October 2015
- Published by Science Publishing Group in American Journal of Internal Medicine
- Vol. 3 (6) , 250-255
Open AccessRelationship Between Neutrophil-Lymphocyte Ratio and Microvascular Complications in Egyptian Patients with Type 2 Diabetes
Several epidemiological studies have shown that chronic inflammation plays a central role in the pathogenesis of diabetes and its various complications. Neutrophil-lymphocyte ratio (NLR) is a novel potential marker in determining inflammation. The aim of this study was to evaluate the relationship between diabetic microvascular complications, namely diabetic retinopathy, nephropathy, neuropathy, and neutrophil-lymphocyte ratio in type 2 diabetic patients. The study took place in the Unit of Diabetes & Metabolism at the Faculty of Medicine, Alexandria University, Alexandria, Egypt, and included a total of 280 subjects, 200 male patients with type 2 diabetes, 108 of them having one or more microvascular complication, and a control group including 80 healthy age and sex-matched subjects. Results of our study showed that neutrophil-lymphocyte ratio (NLR) values were significantly higher in diabetic patients with retinopathy (p<0.001), neuropathy (p=0.025) and nephropathy (p<0.001) than those of diabetic patients without any microvascular complications and healthy control subjects. NLR levels correlated positively with body mass index (BMI) (r=0.436, p<0.001), glycosylated hemoglobin (HbA1c) (r=0.526, p=0.001) and erythrocyte sedimentation rate (ESR) (r=0.396, p=0.017). Based on the results of this study, we can conclude that neutrophil-lymphocyte ratio (NLR), which is an efficient, simple and stable marker of inflammation, can serve as an important predictor for the presence of microvascular complications in Egyptian patients with type 2 diabetes.